WHO "drops" IMPACT's counterfeit drug definition

19 September 2013

The World Health Organization's executive board has dropped an attempt to introduce a new definition of counterfeit medicines, following  concerted pressure from a coalition of India-based generic drugmakers  and the governments of Brazil and India. The proposals of the  International Medical Products Anti-Counterfeiting Taskforce (IMPACT)  had already been amended late last year at a meeting in Bonn, Germany,  to overcome concerns about legitimate generic drugs being accidentally  classified as "fake" (Marketletter December 15, 2008).

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK









Company Spotlight